A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Insulin detemir
Cefaloridine
Cefaloridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Ceftobiprole
Ceftobiprole may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Latamoxef
Latamoxef may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Cephalothin Group
Cephalothin Group may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Hydrolyzed Cephalothin
Hydrolyzed Cephalothin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Cefoxitin
Cefoxitin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Cefotetan
Cefotetan may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Cefonicid
Cefonicid may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Insulin detemir
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Levomilnacipran.
Insulin detemir
Imipramine oxide
The risk or severity of adverse effects can be increased when Imipramine oxide is combined with Levomilnacipran.
Insulin detemir
Melitracen
The risk or severity of adverse effects can be increased when Melitracen is combined with Levomilnacipran.
Insulin detemir
Quinupramine
The risk or severity of adverse effects can be increased when Quinupramine is combined with Levomilnacipran.
Insulin detemir
Amitriptylinoxide
The risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Levomilnacipran.
Insulin detemir
Dimetacrine
The risk or severity of adverse effects can be increased when Dimetacrine is combined with Levomilnacipran.
Insulin detemir
Iprindole
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Iprindole.
Insulin detemir
Lofepramine
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lofepramine.
Insulin detemir
Dibenzepin
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dibenzepin.
Insulin detemir
Oxaprotiline
The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Oxaprotiline.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3